SKYE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 14:49):

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases...

Stats
Today's Volume	82 345.00
Average Volume	41 840.00
Market Cap	12.63B
EPS	$0 ( 2024-03-31 )
Next earnings date	( $0 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.150
ATR14	$0.0570 (0.44%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-13	5am Partners Vii, Llc	Buy	450 000	Common Stock
2024-03-13	Schwab Andrew J.	Buy	450 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	100 000	Common Stock
2024-02-29	Grayson Paul A.	Buy	35 000	Stock Option (Right to Buy)
2024-02-29	Charych Deborah H.	Buy	35 000	Stock Option (Right to Buy)

INSIDER POWER
98.75
Last 83 transactions
Buy: 1 749 377 489 \| Sell: 16 641 486

Volume Correlation

Long: 0.04 (neutral)

Short: 0.86 (strong)

Signal:(50.952) Same movement expected

Skye Bioscience, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Skye Bioscience, Inc. Correlation - Currency/Commodity

-0.02
( neutral )

-0.08
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.33
( neutral )

-0.59
( weak negative )

Skye Bioscience, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-114 998 (0.00 %)
EPS:	$-9.82

Q3	2023
Revenue:	$0
Gross Profit:	$-28 789.00 (0.00 %)
EPS:	$-3.17

Q2	2023
Revenue:	$0
Gross Profit:	$-33 917.00 (0.00 %)
EPS:	$-0.800

Q1	2023
Revenue:	$0
Gross Profit:	$-33 174.00 (0.00 %)
EPS:	$-1.550

Financial Reports:

No articles found.

Skye Bioscience, Inc.

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.